PL-6983

PL-6983 is a synthetic peptide and selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction.[1][2][3] It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials.[1][3] Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models.[1][3] The drug has reportedly been in pre-clinical development for all medical indications since 2008.[4] Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983."[5] The chemical structure of PL-6983 has yet to be made public.

PL-6983
Clinical data
Routes of
administration		Subcutaneous injection
Identifiers
CAS Number

See also

References
  1. Natasha Mitchner (2009). Hypoactive Sexual Desire Disorder in Women: Implications for Family Practice (PDF). Dowden Health Media.
  2. Simon JA (2009). "Opportunities for intervention in HSDD" (PDF). J Fam Pract. 58 (7 Suppl Hypoactive): S26–30. PMID 19825316.
  3. Michael L. Krychman; Sandra Finestone (25 October 2010). 100 Questions & Answers About Breast Cancer Sensuality, Sexuality and Intimacy. Jones & Bartlett Publishers. pp. 120–. ISBN 978-1-4496-1936-7.
  4. "Research programme: sexual dysfunction therapy - Palatin Technologies - AdisInsight". adisinsight.springer.com. Retrieved 2019-06-06.
  5. "Palatin Technologies - PL-6983 for Female Sexual Dysfunction". web.archive.org. 2015-05-26.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.